Mineralys Therapeutics (NASDAQ:MLYS) Director Alexander Gold Sells 15,000 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Alexander Gold sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $43.98, for a total value of $659,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock opened at $44.29 on Friday. The firm has a market cap of $3.51 billion, a PE ratio of -15.01 and a beta of 0.40. Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $47.65. The stock has a fifty day moving average price of $40.05 and a 200-day moving average price of $23.78.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. As a group, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of large investors have recently made changes to their positions in MLYS. Smartleaf Asset Management LLC grew its position in shares of Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in Mineralys Therapeutics by 297.5% during the 1st quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company’s stock worth $25,000 after purchasing an additional 1,190 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the period. Russell Investments Group Ltd. grew its holdings in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after buying an additional 3,241 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after buying an additional 1,197 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

MLYS has been the subject of several research analyst reports. Wells Fargo & Company raised their price target on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday. Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Bank of America upped their price target on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group increased their price target on Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.67.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.